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OBJECTIVES: To compare divalproex sodium and valproic acid
for therapeutic patterns, persistence rates, and predictors of 
hospitalization among bipolar patients on monotherapy in the
Veterans Affairs Health care system. METHODS: Using VA
administrative data bases, we conducted a retrospective incep-
tion cohort study of VA patients’ °Y´ 18 years of age who had at
least one outpatient diagnoses of bipolar disorder and two con-
tinuous prescription records for the study drugs in the VA PBM
pharmacy database during the study period of April 1, 2001 to
September 30 2003. Persistence for the comparative drugs was
reported as continuous variable and compared using t-tests.
Logistic regression models were used to examine the risk of hos-
pitalization whereas Cox proportional hazard regression models
were used to evaluate the time to hospitalization and time to
interruption of therapy for the two drug groups. RESULTS: We
identiﬁed 4, 624 bipolar patients on monotherapy with valproic
acid (n = 4036) and divalproex sodium (n = 588) during the
study period. The descriptive statistics included sociodemo-
graphics, disability and comorbidity status and were similar for
the two groups. For the crude persistence rates there were no sta-
tistically signiﬁcant differences between divalproex sodium (120
days) and valproic acid (110 days). The logistic regression model
for risk of hospitalization showed no statistically signiﬁcant dif-
ference between the two comparators (OR = 1.06, 95% CI =
0.787–1.444). The Cox model for time to interruption of therapy
showed an insigniﬁcant hazard ratio for divalproex sodium
versus valproic acid (HR = 0.928, 95% CI = 0.844–1.020) and
for time to hospitalization also no statistically signiﬁcant differ-
ence in the hazard ratio for the two drugs (HR = 0.984, 95% CI
= 0.784–1.295). CONCLUSION: The study showed a compa-
rable proﬁle of generic valproic acid with divalproex sodium for
persistence and predictors of hospitalization for bipolar patients
on monotherapy in the VA. Results have important health care
implications for treatment and costs.
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OBJECTIVES: Given the high incidence of post-stroke depres-
sion (PSD), its serious sequalae, and inherent problems with
diagnosis, prophylactic use of antidepressants may be a viable
management strategy in patients experiencing stroke. The
purpose of this study was to assess the prophylactic effects 
of antidepressants in non-depressed patients with stroke.
METHODS: A meta-analysis of randomized placebo-controlled
trials (RCTs) evaluating the prophylactic effects of antidepres-
sants in non-depressed patients with stroke was conducted. Lit-
erature searches in MEDLINE, PubMed, CINAHL, PsycINFO,
EMBASE, Cochrane library, and CNKI from 1950 to August
2006 were used to identify the relevant studies. Outcome mea-
sures included the occurrence rate of newly developed PSD cases
and severity of depressive symptoms as indicated by mean
depression rating scales scores. The effect size was presented as
rate difference (RD) or weighted mean difference (WMD).
RESULTS: From 10 RCTs, a total of 703 non-depressed patients
after stroke were identiﬁed. The pooled occurrence rate of newly
developed PSD cases in the intervention and control groups were
12.54% (41/327) and 29.17% (91/312), respectively (pooled RD
= −0.17, 95% CI: −0.26 to −0.08). Prophylactic effects of anti-
depressants were not related to duration of use (coefﬁcient of
Pearson’ correlation [ã] = 0.57, p = 0.11). CONCLUSION: Anti-
depressant prophylaxis is associated with a signiﬁcant reduction
in the occurrence rate of newly developed PSD, suggesting anti-
depressants may be considered along with other vascular pre-
ventive strategies in management of stroke patients.
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OBJECTIVES: With 50–70% antipsychotic prescriptions
written for off-label purposes, the objective of this study is to
explore the pattern and the outcomes of adverse events (ADEs)
associated with antipsychotic off-label use. METHODS: A ret-
rospective pharmaco-vigilance analysis was conducted using the
FDA Adverse Event Reporting System (AERS) data between
April 2004 and March 2006. ADE cases associated with antipsy-
chotic medications were ﬁrst identiﬁed based on the role of the
medication in precipitating the ADEs (primary and secondary
suspects) and then categorized according to their intended indi-
cations as off-label/on-label uses. Thereafter, the most frequently
reported off-label antipsychotic uses associated with ADEs were
explored, and their clinical outcomes were examined and com-
pared with on-label antipsychotic ADE cases. RESULTS: Out of
27,700 ADEs involving antipsychotic medications, antipsy-
chotics were the primary suspect in 7519 cases and secondary
suspect in 2409 cases (Total: 9928). Atypical antipsychotics
accounted for majority of the cases (9122, 91.8%) with clozap-
ine (2983, 30.1%) being the most frequently reported antipsy-
chotic medication followed by quetiapine (2186, 22.0%) and
risperidone (2153, 21.7%). Off-label use afﬂicted half of the
reported ADEs cases (4767, 48%). The top three reported off-
label indications associated with ADEs include psychotic and
schizoaffective disorders (1372, 28.8%), mood disorders (1105,
23.2%) and cognitive disorders (406, 8.5%). These ADEs could
result into severe clinical outcomes. Of total 4767 ADEs associ-
ated with off-label use, (1942, 40.7%) involved hospitalizations
and (1043, 21.9% ) deaths. Similar pattern of clinical outcomes
were found in ADE cases associated with on-label antipsychotic
use. CONCLUSION: Most of the off-label antipsychotic-related
ADEs reported to FDA is associated with using atypical antipsy-
chotic medications for treating schizoaffective disorder, bipolar
disorder, depression and dementia. More than half of these ADEs
resulted in severe clinical outcomes such as hospitalizations and
death. Therefore, the risk beneﬁt ratio should be seriously con-
sidered when physicians prescribe antipsychotics for off-label
purposes.
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OBJECTIVES: To compare the risk of treatment-emergent dia-
betes (TED) in schizophrenic patients treated with atypical
(AAP) versus typical antipsychotic (TAP) medications.
METHODS: We conducted a retrospective database analysis on
episodes of care initiated after 1/1/2000 using data from Medi-
Cal. Our analysis included episodes for patients 18 years of age
or older, diagnosed with schizophrenia, who switched medica-
tions after a minimum “wash out” period of 15 days and had
no evidence of diabetes in the previous 6 months. We used a
simultaneous bivariate probit model to estimate the risk of TED
in patients treated with AAP in comparison to TAP. If the error
